



health

Department:
Health
REPUBLIC OF SOUTH AFRICA



Reference: 2026/10/23/EDP/01

Enquiries:

Stock queries:

Ms Babalwa Melitafa

E-mail: Babalwa.Melitafa@health.gov.za

Contracting queries:

Ms Marione Schonfeldt

E-mail: marione.schonfeldt@health.gov.za

Clinical queries:

Essential Drugs Programme

E-mail: SAEDP@health.gov.za

NOTICE: RIVAROXABAN 10MG, 15MG AND 20MG TABLETS – SUPPLY CHALLENGE

The Adult Hospital Level Standard Treatment Guidelines (STGs) and Essential Medicines List (EML) currently recommends the use of oral rivaroxaban tablets for specific indications such as the management of venous thrombo-embolism (*refer to the Adult Hospital Level Chapter 2 BBFO Section 2.8 Venous thrombo-embolism*) and atrial fibrillation (*refer to the Adult Hospital Level Chapter 3 cardiovascular system Section 3.3.1.1 Atrial fibrillation*).

Viatrix Healthcare (Pty) Ltd, the current contracted supplier, on national tender, is currently unable to supply rivaroxaban 10mg, 15mg and 20mg tablets. The supplier anticipates resuming the supply of rivaroxaban 10 mg and 20 mg in November 2026, while rivaroxaban 15 mg is expected in December 2026.

All three products are, however, available for procurement through the Provincial Pharmaceutical Quotations (PPQ) process (with the following validity period: 28 August 2026 to 30 December 2026). The PPQs are awarded to three suppliers, namely Innovata Pharmaceuticals (Pty) Ltd, Bayer (Pty) Ltd and Adcock Ingram Healthcare (Pty) Ltd. ***Refer to the annexures below.***

The volumes on the PPQs should be sufficient to meet demand until Viatrix Healthcare (Pty) Ltd is able to resume supply on tender. **However, there is a potential risk of intermittent supply with the rivaroxaban 10mg strength via the PPQ process. Should stock shortages be experienced with rivaroxaban 10mg tablets, refer to the guidance on alternative therapy as outlined below.**

Adult Hospital Level Chapter 2: Blood and Blood Forming Organs (BBFO) Section 2.8.1 Venous Thrombo-embolism – Prophylaxis	
Current Standard Treatment Guideline Recommendation	Alternative Therapeutic Options
For patients hospitalised due to medical illnesses at high risk of VTE: ▪ Direct acting oral anticoagulant (DOAC), e.g.: • Rivaroxaban, oral, 10 mg daily with food while hospitalised. For elective total hip arthroplasty: ▪ Direct acting oral anticoagulant (DOAC), e.g. • Rivaroxaban, oral, 10 mg daily with food. • Initiated 6–10 hours post-surgery for duration of admission or a maximum of 10 days. Following rivaroxaban, prescribe aspirin: • Aspirin, oral, 150 mg daily for 28 days on discharge from hospital. For elective total knee arthroplasty: Total duration of prophylactic therapy: 14 days. ▪ Direct acting oral anticoagulant (DOAC), e.g. • Rivaroxaban, oral, 10 mg daily with food. • Initiate anticoagulation 6–10 hours post-surgery for the duration of hospital admission for a minimum of 2 days and a maximum of 7 days. Following rivaroxaban, prescribe aspirin: • Aspirin, oral, 150 mg daily. • Treat with aspirin for remainder of VTE prophylaxis period, i.e. 14 days in total including days on rivaroxaban.	For patients hospitalised due to medical illnesses at high risk of VTE: ▪ Low molecular weight heparin, e.g.: • Enoxaparin, SC, 40 mg daily. ○ In morbid obesity, dosing of LMWH should be individualised, in discussion with a specialist. ○ Renal impairment (eGFR < 30 mL/min): adjust dose to 20 mg daily. OR • Unfractionated heparin, SC, 5 000 units 12 hourly. ○ Dose adjustment is generally not required for renal impairment. ○ Monitor for bleeding complications. For elective total hip arthroplasty: ▪ Low molecular weight heparin, e.g.: • Enoxaparin, SC, 40 mg daily. ○ Initiated 6-10 hours post-surgery for duration of admission or maximum of 10 days. ○ In morbid obesity, dosing of LMWH should be individualised, in discussion with a specialist. ○ Renal impairment (eGFR < 30 mL/min): adjust dose to 20 mg daily. OR • Unfractionated heparin, SC, 5 000 units 12 hourly. ○ initiated 6-10 hours post-surgery for duration of admission or maximum of 10 days. ○ Dose adjustment is generally not required for renal impairment. ○ Monitor for bleeding complications. Following enoxaparin OR unfractionated heparin, ▪ Prescribe aspirin: • Aspirin, oral, 150 mg daily for 28 days on discharge from hospital. For elective total knee arthroplasty: ▪ Low molecular weight heparin, e.g.: • Enoxaparin, SC, 40 mg daily. ○ Initiated 6-10 hours post-surgery for duration of admission for a minimum of 2 days and a maximum of 7 days. ○ In morbid obesity, dosing of LMWH should be individualised, in discussion with a specialist. ○ Renal impairment (eGFR < 30 mL/min): adjust dose to 20 mg daily. OR • Unfractionated heparin, SC, 5 000 units 12 hourly. ○ Initiated 6-10 hours post-surgery for duration of admission for a minimum of 2 days and a maximum of 7 days. ○ Dose adjustment is generally not required for renal impairment. ○ Monitor for bleeding complications. Following enoxaparin OR unfractionated heparin, ▪ Prescribe aspirin: • Aspirin, oral, 150 mg daily • Treat with aspirin for remainder of VTE prophylaxis period, i.e. 14 days in total including days on enoxaparin/heparin.

NOTICE: RIVAROXABAN 10MG, 15MG AND 20MG TABLETS – SUPPLY CONSTRAINT

Circular Implementation and Dissemination

Provinces and healthcare facilities are requested to distribute and communicate this information in consultation with the Pharmaceutical and Therapeutics Committees and all other relevant stakeholders.

Note: *Any further updates or changes regarding the supply constraints will be communicated accordingly.*

Kind regards

K. Jamaloodien

MS K JAMALOODIEN
CHIEF DIRECTOR: HEALTH PRODUCTS PROCUREMENT
DATE: 23/10/2020



health

Department:
Health
REPUBLIC OF SOUTH AFRICA

Private Bag X828, PRETORIA, 0001 Dr AB Xuma Building 1112 Voortrekker Road, Pretoria Townlands 351-JR, PRETORIA, 0187
Tel (012) 395 8000, Fax (012) 395 8918

To: Depot Managers; Heads of Pharmaceutical Services

PPQ57/2026: Rivaroxaban; 10mg; Tablet; 30 Tablets

Rivaroxaban; 15mg; Tablet; 42 Tablets is awarded as Item 310 to Viatris Healthcare(Pty) Ltd under Contract HP09-2026SD. The suppliers are experiencing supply constraints as per the pipeline report submitted by suppliers on the 17th of July 2026. In an effort to assist the provinces, the National Department of Health (NDoH) has solicited quotation/s from relevant supplier/s, aligned with the Five Pillars of Procurement contained in the Public Finance Management Act, 1999. (*Value for Money / Open and Effective Competition / Ethics and Fair Dealing / Accountability and Reporting / Equity*).

Participating Authorities are advised to procure stock from the supplier/s listed below, in accordance with the applicable provincial supply chain management processes, in instances where the contracted supplier/s are unable to fulfil the Special Requirements and Conditions of Contract (SRCC). The PPQ and the quoted price shall remain valid until 30 December 2026 or until the quoted quantities are depleted, whichever occurs first. Participating Authorities must confirm stock availability with the supplier before placing any orders. Orders may only be placed if stock is confirmed to be available at that specific time.

PPQ57/2026: Rivaroxaban; 10mg; Tablet; 30 Tablets

These quotations are listed below:

Date initiated: 24 August 2026				
Expiry date: 30 December 2026 or upon depletion of quoted quantities				
NSN: 181870433		Item Description: PPQ57/2026: Rivaroxaban; 10mg; Tablet; 30 Tablets		
No	Supplier name	Quantity Quoted	Status	Contact person
1.	Bayer(Pty) Ltd	12831	• Available in 14 days: 1500 • Available in 14 days: 1500 • Available in 14 days: 1500 • Available in 14 days: 1500	Za_tenders@bayer.com
2.	Adcock Ingram Health care (Pty) Ltd	12831	• Available in 14 days: 1000	Dorah.Malatji@adcock.com
3.	Innovata Pharmaceuticals (Pty) Ltd	12831	• Available in 56 days: 12831	anulka.m@innovata.co.za

For enquiries, please contact the Contract Manager, Bonolo Serumula on Bonolo.Serumula@Health.gov.za

Yours sincerely


MS. KHADIJA JAMALOODIEN

CHIEF DIRECTOR: HEALTH PRODUCTS PROCUREMENT

DATE: 08/01/2026



health

Department:
Health
REPUBLIC OF SOUTH AFRICA

Private Bag X828, PRETORIA, 0001 Dr AB Xuma Building 1112 Voortrekker Road, Pretoria Townlands 351-JR, PRETORIA, 0187
Tel (012) 395 8000, Fax (012) 395 8918

To: Depot Managers; Heads of Pharmaceutical Services

PPQ56/2026: Rivaroxaban; 15mg; Tablet; 42 Tablets

Rivaroxaban; 15mg; Tablet; 42 Tablets is awarded as Item 311 to Viartis Healthcare(Pty) Ltd under Contract HP09-2026SD. The suppliers are experiencing supply constraints as per the pipeline report submitted by suppliers on the 17th of July 2026. In an effort to assist the provinces, the National Department of Health (NDoH) has solicited quotation/s from relevant supplier/s, aligned with the Five Pillars of Procurement contained in the Public Finance Management Act, 1999. (*Value for Money / Open and Effective Competition / Ethics and Fair Dealing / Accountability and Reporting / Equity*).

Participating Authorities are advised to procure stock from the supplier/s listed below, in accordance with the applicable provincial supply chain management processes, in instances where the contracted supplier/s are unable to fulfil the Special Requirements and Conditions of Contract (SRCC). The PPQ and the quoted price shall remain valid until 30 December 2026 or until the quoted quantities are depleted, whichever occurs first. Participating Authorities must confirm stock availability with the supplier before placing any orders. Orders may only be placed if stock is confirmed to be available at that specific time.


PPQ56/2026: Rivaroxaban; 15mg; Tablet; 42 Tablets

These quotations are listed below:

Date initiated: 24 August 2026				
Expiry date: 30 December 2026 or upon depletion of quoted quantities				
NSN: 222001163		Item Description: Rivaroxaban; 15mg; Tablet; 42 Tablets		
No	Supplier name	Quantity Quoted	Status	Contact person
1.	Bayer(Pty) Ltd	1314	• Available in 14 days: 1314	Za_tenders@bayer.com
2.	Adcock Ingram Health care (Pty) Ltd	1314	• Available in 14 days: 1314	Dorah.Malatji@adcock.com
3.	Innovata Pharmaceuticals (Pty) Ltd	1314	• Available in 56 days: 1314	anulka.m@innovata.co.za

For enquiries, please contact the Contract Manager, Bonolo Serumula on Bonolo.Serumula@Health.gov.za

Yours sincerely



MS. KHADIJA JAMALOODIEN

CHIEF DIRECTOR: HEALTH PRODUCTS PROCUREMENT

DATE: 20/08/2026



health

Department:
Health
REPUBLIC OF SOUTH AFRICA

Private Bag X828, PRETORIA, 0001 Dr AB Xuma Building 1112 Voortrekker Road, Pretoria Townlands 351-JR, PRETORIA, 0187
Tel (012) 395 8000, Fax (012) 395 8918

To: Depot Managers; Heads of Pharmaceutical Services

PPQ55/2026: Rivaroxaban; 20mg; Tablet; 30 Tablets

Rivaroxaban; 20mg; Tablet; 30 Tablets is awarded as Item 312 to Viatrix Healthcare(Pty) Ltd under Contract HP09-2026SD. The suppliers are experiencing supply constraints as per the pipeline report submitted by suppliers on the 17th of July 2026. In an effort to assist the provinces, the National Department of Health (NDoH) has solicited quotation/s from relevant supplier/s, aligned with the Five Pillars of Procurement contained in the Public Finance Management Act, 1999. (*Value for Money / Open and Effective Competition / Ethics and Fair Dealing / Accountability and Reporting / Equity*).

Participating Authorities are advised to procure stock from the supplier/s listed below, in accordance with the applicable provincial supply chain management processes, in instances where the contracted supplier/s are unable to fulfil the Special Requirements and Conditions of Contract (SRCC). The PPQ and the quoted price shall remain valid until 30 December 2026 or until the quoted quantities are depleted, whichever occurs first. Participating Authorities must confirm stock availability with the supplier before placing any orders. Orders may only be placed if stock is confirmed to be available at that specific time.


PPQ55/2026: Rivaroxaban; 20mg; Tablet; 30 Tablets

These quotations are listed below:

Date initiated: 24 August 2026				
Expiry date: 30 December 2026 or upon depletion of quoted quantities				
NSN: 222001855		Item Description: Rivaroxaban; 20mg; Tablet; 30 Tablets		
No	Supplier name	Quantity Quoted	Status	Contact person
1.	Bayer(Pty) Ltd	13101	• Available in 14 days: 13101	Za_tenders@bayer.com
2.	Adcock Ingram Health care (Pty) Ltd	13101	• Available in 14 days: 9000	Dorah.Malatji@adcock.com
3.	Innovata Pharmaceuticals (Pty) Ltd	13101	• Available in 56 days: 13101	anulka.m@innovata.co.za

For enquiries, please contact the Contract Manager, Bonolo Serumula on Bonolo.Serumula@Health.gov.za

Yours sincerely


MS. KHADIJA JAMALOODIEN

CHIEF DIRECTOR: HEALTH PRODUCTS PROCUREMENT

DATE: 2018/2026